PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk

Abroad (travel likely)RecruitingPHASE2

Conditions

Renal Cell Carcinoma (RCC) · Metastatic Renal Cell Carcinoma (mRCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, Nanjing, Jiangsu, China
Contact: Study coordinator (Le Qu, M.D) · septsoul@hotmail.com · +86 15720625951

Study leads

Le Qu
Study Chair
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Irvine, United States · Boston, United States

Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

Renal Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Dallas, United States